[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644432":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":38,"responsibleParty":54,"collaborators":25,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":25,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":25,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":41,"whyStopped":25,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Sohag University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Norepinehrine group","EXPERIMENTAL","• NE group: norepinephrine infusion at 8 µg\u002Fmin. Infusion will continue for 45 minutes after spinal anesthesia.",[13],"Drug: Norepinephrine",{"label":15,"type":10,"description":16,"interventionNames":17},"Phenylepherine group","PhE group: phenylephrine infusion at 100 µg\u002Fmin Infusion will continue for 45 minutes after spinal anesthesia.",[18],"Drug: Phenylephrine",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Norepinephrine","norepinephrine infusion at 8 µg\u002Fmin. Infusion will continue for 45 minutes after spinal anesthesia.",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Phenylephrine","phenylephrine infusion at 100 µg\u002Fmin. Infusion will continue for 45 minutes after spinal anesthesia.",[15],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Ahmed Abdelhamed Faress, Resident","CONTACT","01065080913","drahmedfaress23896@gmail.com",{"name":37,"role":33,"phone":25,"phoneExt":25,"email":25},"Fawzy Abbas Badawy, Professor",[39],{"facility":40,"status":41,"city":42,"state":25,"zip":25,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Sohag university hospital","RECRUITING","Sohag","Egypt","EG",{"type":46,"coordinates":47},"Point",[48,49],31.69478,26.55695,{"lat":49,"lon":48},[52],{"name":53,"role":33,"phone":25,"phoneExt":25,"email":25},"Mohamed N Hamdoun, Professor",{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Ahmed Abdelhameed Fares","Resident of anaesthesia. Surgical ICU and pain managment at sohag university hospital","100644432","phase-4-comparison-of-norepinehrine-versus-phenylepherine-infusion-for-prevention-of-post-spinal-hypotension-100644432",false,"NCT07662408","Comparison of Norepinehrine Versus Phenylepherine Infusion for Prevention of Post-spinal Hypotension","Comparison of Norepinephrine Versus Phenylephrine Infusion for Prevention of Hypotension Due to Subarachnoid Block in Elderly Patients Undergoing Orthopedic Hip Surgery:A Prospective Randomized Trial","Inclusion Criteria:\n\n1. Age 60 years or older.\n2. ASA physical status I-III.\n3. Scheduled for elective hip surgery under subarachnoid block.\n4. Willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. Patient refusal.\n2. Contraindications to subarachnoid block.\n3. Severe cardiac disease.\n4. Uncontrolled hypertension.\n5. Allergy to study drugs.\n6. Emergency surgery.\n7. Monoamine oxidase inhibitor use.\n8. Cognitive impairment preventing informed consent.",true,"ALL","60 Years","100 Years",{"count":70,"type":71},62,"ESTIMATED","INTERVENTIONAL",[74],"PHASE4","This prospective randomized double-blinded clinical trial aims to compare the efficacy and hemodynamic effects of prophylactic norepinephrine infusion versus phenylephrine infusion for prevention of spinal anesthesia-induced hypotension in elderly patients undergoing elective orthopedic hip surgery under subarachnoid block. Sixty-two patients aged 60 years or older will be randomly assigned into two equal groups to receive either norepinephrine infusion (8 µg\u002Fmin) or phenylephrine infusion (100 µg\u002Fmin) immediately after spinal anesthesia. The primary outcome is the mean heart rate during vasopressor infusion, while secondary outcomes include incidence of hypotension, severe hypotension, bradycardia, reactive hypertension, intraoperative fluid requirements, blood loss, transfusion requirements, and postoperative nausea and vomiting. Hemodynamic parameters will be monitored throughout surgery to evaluate the safety and effectiveness of both vasopressor strategies.",[77,78],"Patients Undergoing Orthopedic Hip Surgery Under Spinal Anesthesia","Orthopedic Hip Sugery in Eldely Patients",[80],"Norepinehrine versus phenylepherine infusion in management of post-spinal hypotension","2026-06-22",{"date":83,"type":84},"2026-06-23","ACTUAL",{"date":86,"type":84},"2026-05-22",{"date":88,"type":71},"2027-03-14",{"name":5,"class":6},1]